Bailard’s bluebird bio BLUE Stock Holding History

Bailard’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-865	Closed	-$214K	–	726
2021 Q3	$214K	Buy	865 +108	+14%	+$30.9K	0.01%	657
2021 Q2	$313K	Buy	+757	New	+$300K	0.01%	509
2020 Q4	–	Sell	-471	Closed	-$329K	–	629
2020 Q3	$329K	Hold	471	–	–	0.02%	367
2020 Q2	$372K	Hold	471	–	–	0.02%	311
2020 Q1	$280K	Hold	471	–	–	0.02%	332
2019 Q4	$535K	Buy	+471	New	+$512K	0.03%	262
2019 Q3	–	Sell	-154	Closed	-$254K	–	534
2019 Q2	$254K	Hold	154	–	–	0.02%	454
2019 Q1	$315K	Buy	+154	New	+$271K	0.02%	410
2018 Q4	–	Sell	-154	Closed	-$292K	–	498
2018 Q3	$292K	Hold	154	–	–	0.02%	471
2018 Q2	$314K	Hold	154	–	–	0.02%	440
2018 Q1	$342K	Sell	154 -39	-20%	-$99.2K	0.02%	397
2017 Q4	$445K	Buy	+193	New	+$392K	0.03%	326
2016 Q1	–	Sell	-386	Closed	-$321K	–	263
2015 Q4	$321K	Buy	+386	New	+$386K	0.14%	164

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bailard's BLUE Position: Q4 2021 in Review

Bailard sold out of bluebird bio (BLUE) in Q4 2021, closing a stake of 865 shares — an estimated $214K sold.

Bailard first reported a position in BLUE in Q4 2015 and held it in 13 quarters. The position peaked at $535K in Q4 2019. 172 funds tracked by Wall St. Rank hold BLUE as of Q4 2021.

Bailard reported no remaining bluebird bio position as of Q4 2021 after selling out during the quarter.
Bailard sold 865 bluebird bio shares in Q4 2021, an estimated $214K.
Bailard first reported a position in bluebird bio in Q4 2015 and held it in 13 quarters.
Bailard's bluebird bio position peaked at $535K in Q4 2019.
172 funds tracked by Wall St. Rank held bluebird bio as of Q4 2021.

Based on Bailard's 13F filing for Q4 2021, filed 10 Feb 2022.